{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T05:50:17Z","timestamp":1789624217359,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Hematology"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1053\/j.seminhematol.2010.06.002","type":"journal-article","created":{"date-parts":[[2010,9,29]],"date-time":"2010-09-29T05:04:19Z","timestamp":1285736659000},"page":"344-353","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?"],"prefix":"10.1053","volume":"47","author":[{"given":"Elias","family":"Jabbour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1053\/j.seminhematol.2010.06.002_bib1","first-page":"205","article-title":"Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia","volume":"3","author":"Ramchandren","year":"2009","journal-title":"Biologics Targets Ther"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib2","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1056\/NEJM199904293401706","article-title":"Chronic myeloid leukemia","volume":"340","author":"Sawyers","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib3","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJMct071828","article-title":"BCR-ABL tyrosine kinase inhibitors for chronic myelogenous leukemia","volume":"357","author":"Schiffer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11523-008-0100-y","article-title":"Treatment selection after imatinib resistance in chronic myeloid leukemia","volume":"4","author":"Jabbour","year":"2009","journal-title":"Targ Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1053\/j.seminhematol.2006.12.007","article-title":"The biology of chronic myelogenous leukemia: implications for imatinib therapy","volume":"44","author":"Alvarez","year":"2007","journal-title":"Semin Hematol"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib6","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib7","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib8","doi-asserted-by":"crossref","first-page":"973","DOI":"10.4065\/81.7.973","article-title":"Chronic myeloid leukemia: diagnosis and treatment","volume":"81","author":"Quintas-Cardama","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib9","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.hoc.2004.03.012","article-title":"Clonal evolution in chronic myelogenous leukemia","volume":"18","author":"Cortes","year":"2004","journal-title":"HematolOncol Clin North Am"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib10","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O'Brien","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib11","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","article-title":"Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1756-8722-2-10","article-title":"New dosing schedules of dasatinib for CML and adverse event management","volume":"2","author":"Wong","year":"2009","journal-title":"J Hematol Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib13","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib14","series-title":"Gleevec","year":"2009"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib15","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib16","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients 534 receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.biocel.2007.10.001","article-title":"Overcoming kinase resistance in chronic myeloid leukemia","volume":"40","author":"Lee","year":"2008","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib19","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib20","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1038\/sj.leu.2404318","article-title":"Frequency and clinical significance of BCRABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate","volume":"20","author":"Jabbour","year":"2006","journal-title":"Leukemia"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib21","doi-asserted-by":"crossref","first-page":"3530","DOI":"10.1182\/blood.V99.10.3530","article-title":"Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study","volume":"99","author":"Sawyers","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib22","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","article-title":"Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study","volume":"99","author":"Talpaz","year":"2002","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib23","unstructured":"2009. NccnNCpgioCMLV."},{"key":"10.1053\/j.seminhematol.2010.06.002_bib24","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.blre.2005.01.008","article-title":"Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia","volume":"20","author":"Hughes","year":"2006","journal-title":"Blood Rev"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/cncr.23238","article-title":"Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?","volume":"112","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib27","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas-Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib28","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1002\/cncr.24066","article-title":"Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib29","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood-2008-04-154344","article-title":"Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia post cytogenetic failure on standard-dose imatinib therapy","volume":"113","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib30","series-title":"Sprycel (dasatinib)","year":"2007"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib31","series-title":"Dasatinib prescribing information","year":"2008"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib32","doi-asserted-by":"crossref","first-page":"2303","DOI":"10.1182\/blood-2006-09-047266","article-title":"Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy","volume":"109","author":"Hochhaus","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib33","first-page":"372","article-title":"Dasatinib long-term efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) with resistance or intolerance to imatinib: a two-year update of the START-C study","volume":"93","author":"Cervantes","year":"2008","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib34","doi-asserted-by":"crossref","first-page":"4136","DOI":"10.1002\/cncr.24504","article-title":"Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R)","volume":"115","author":"Kantarjian","year":"2009","journal-title":"Cancer"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib35","doi-asserted-by":"crossref","first-page":"358s","DOI":"10.1200\/jco.2007.25.18_suppl.7004","article-title":"Dasatinib 50 mg or 70 mg BID compared to 100 mg or 140 mg QD in patients with CML in chronic phase (CP) who are resistant or intolerant to imatinib: one-year results of CA180034","volume":"25","author":"Shah","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib36","doi-asserted-by":"crossref","first-page":"6322","DOI":"10.1182\/blood-2008-11-186817","article-title":"Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib37","doi-asserted-by":"crossref","unstructured":"Larson RA, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily (QD) has equivalent efficacy and improved safety compared with 70 Mg twice daily (BID) in patients with imatinib-resistant or -intolerant Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): 2-year data from CA180-035. Abstract 2926. Presented at: 50th ASH Annual Meeting. San Francisco, CA; December 6-9, 2008.","DOI":"10.1182\/blood.V112.11.2926.2926"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib38","doi-asserted-by":"crossref","unstructured":"Saglio G, Kantarjian HM, Hochhaus A, et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP): 2-year data from CA180-035. Abstract 3226. Presented at: 50th ASH Annual Meeting. San Francisco, CA; December 6-9, 2008.","DOI":"10.1182\/blood.V112.11.3226.3226"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib39","series-title":"Tasigna","year":"2009"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib40","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa055104","article-title":"Nilotinib in imatinib-resistant CML and Philadelphia chromosome\u2013positive ALL","volume":"354","author":"Kantarjian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib41","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O'Hare","year":"2005","journal-title":"Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib42","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1158\/1078-0432.CCR-07-5015","article-title":"Nilotinib","volume":"14","author":"Deininger","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib43","first-page":"1129","article-title":"Update on imatinib-resistant chronic myeloid leukemia patients in chronic phase (CML-CP) on nilotinib therapy at 24 months: clinical response, safety, and long-term outcomes","volume":"114","author":"Kantarjian","year":"2009","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"suppl 2","key":"10.1053\/j.seminhematol.2010.06.002_bib44","first-page":"256","article-title":"Nilotinib in chronic myeloid leukemia patients in accelerated phase (CML-AP) with imatinib resistance or intolerance: 24-month follow-up results of a phase 2 study","volume":"94","author":"Hochhaus","year":"2009","journal-title":"Haematologica"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib45","first-page":"1098","article-title":"Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myelogenous leukemia (CML) with resistance or intolerance to imatinib","volume":"112","author":"Cortes","year":"2008","journal-title":"ASH Annual Meeting Abstracts"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib46","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1182\/blood.V114.22.643.643","article-title":"A phase 1 trial of oral AP24534 in patients with refractory chronic myeloid leukemia and other hematologic malignancies: first results of safety and clinical activity against T315I and resistant mutations","volume":"114","author":"Cortes","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib47","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1182\/blood.V114.22.644.644","article-title":"Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in imatinib-resistant chronic myeloid leukemia (CML) patients who harbor the Bcr-Abl T315I mutation-results of an ongoing multicenter phase 2\/3 study","volume":"114","author":"Cortes-Franco","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib48","doi-asserted-by":"crossref","unstructured":"Cortes-Franco J, Raghunadharao D, Parikh P, et al. Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors: results of a multicenter phase 2\/3 study. Abstract 861. Program and abstracts of the 51st American Society of Hematology Annual Meeting and Exposition; December 5-8, 2009; New Orleans, LA.","DOI":"10.1182\/blood.V114.22.861.861"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib49","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood-2008-06-162388","article-title":"European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor","volume":"112","author":"Marin","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib50","unstructured":"Alvarado Y, Kantarjian H, O'Brien S, et al. Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase."},{"key":"10.1053\/j.seminhematol.2010.06.002_bib51","doi-asserted-by":"crossref","first-page":"4005","DOI":"10.1182\/blood-2007-03-080838","article-title":"Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors","volume":"110","author":"Cortes","year":"2007","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib52","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood-2007-11-123950","article-title":"Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib53","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1182\/blood-2009-01-197715","article-title":"Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib54","first-page":"e51","article-title":"Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome\u2013positive leukemia","volume":"24","author":"Soverini","year":"2006","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib55","doi-asserted-by":"crossref","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","article-title":"Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors","volume":"112","author":"Jabbour","year":"2008","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib56","doi-asserted-by":"crossref","first-page":"6914","DOI":"10.1182\/blood-2009-04-214221","article-title":"Dasatinib treatment of chronic phase chronic myeloid leukemia: analysis of responses according to pre-existing BCR-ABL mutations","volume":"114","author":"M\u00fcller","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib57","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.1182\/blood.V114.22.3298.3298","article-title":"Prognostic factors for progression-free survival in patients with imatinib-resistant or \u2013intolerant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib based on 24 month data","volume":"113","author":"Kantarjian","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib58","first-page":"210","article-title":"Predictive factors for response and outcome in patients (pts) treated with second generation tyrosine kinase inhibitors (2-TKI) for chronic myeloid leukemia in chronic phase (CML-CP) post imatinib failure","volume":"114","author":"Jabbour","year":"2009","journal-title":"Blood"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib59","doi-asserted-by":"crossref","first-page":"3908","DOI":"10.1200\/JCO.2007.12.0329","article-title":"Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure","volume":"25","author":"Quintas-Cardama","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib60","doi-asserted-by":"crossref","first-page":"680s","DOI":"10.1200\/jco.2007.25.18_suppl.17503","article-title":"Pleural effusions in patients treated with dasatinib: Results from two institutions, risk factors and management","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1053\/j.seminhematol.2010.06.002_bib61","doi-asserted-by":"crossref","first-page":"17501","DOI":"10.1200\/jco.2007.25.18_suppl.17501","article-title":"Incidence of grade 3\/4 adverse events in imatinib resistant\/intolerant chronic phase CML (CP-CML): a comparison of nilotinib and dasatinib","volume":"25","author":"Carpiuc","year":"2007","journal-title":"J Clin Oncol"}],"container-title":["Seminars in Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000764?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0037196310000764?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T06:20:55Z","timestamp":1758522055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0037196310000764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":60,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0037196310000764"],"URL":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.002","relation":{},"ISSN":["0037-1963"],"issn-type":[{"value":"0037-1963","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?","name":"articletitle","label":"Article Title"},{"value":"Seminars in Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1053\/j.seminhematol.2010.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}